ArticleTherapeutic advances in medical oncology2020

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.

Takahiro Ishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.